For more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
These activities are supported by educational grants from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Novartis and Seagen Inc.
Agenda
Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for Hodgkin and non-Hodgkin lymphomas. Each event will employ an identical format that will include the following elements:
MODULE 1: Chemotherapy-free and newly approved targeted therapies for follicular lymphoma
MODULE 2: Recently approved and promising agents and regimens for the treatment of relapsed/refractory diffuse large B-cell lymphoma
MODULE 3: Efficacy and safety of approved CAR (chimeric antigen receptor) T-cell therapies for B-cell lymphomas
MODULE 4: Incorporation of brentuximab vedotin and immune checkpoint inhibitors into the treatment algorithm for Hodgkin lymphoma; future directions
Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of Hodgkin and non-Hodgkin lymphomas.
Learning Objectives
CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.
FACULTY — Dr Hill has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Bartlett — Advisory Committee: ADC Therapeutics, Genentech, a member of the Roche Group, Seagen Inc; Contracted Research: ADC Therapeutics, Autolus, Bristol-Myers Squibb Company, Celgene Corporation, Forty Seven Inc, Immune Design, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Pharmacyclics LLC, an AbbVie Company, Genentech, a member of the Roche Group, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr Casulo — Contracted Research: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Verastem Inc. Dr Evens — Advisory Committee: Epizyme Inc, HUTCHMED, Karyopharm Therapeutics, Miltenyi Biotec, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Seagen Inc; Consulting Agreements: COTA, Curio Science, Patient Power; Data and Safety Monitoring Board/Committee: AbbVie Inc, Novartis, Pharmacyclics LLC, an AbbVie Company. Dr Flowers — Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Spectrum Pharmaceuticals Inc; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Celgene Corporation, Cellectis, Eastern Cooperative Oncology Group, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, National Cancer Institute, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor, ZIOPHARM Oncology Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma. Dr Friedberg — Data and Safety Monitoring Board/Committee: Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals, Novartis. Dr Kahl — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc. Dr Nastoupil — Advisory Committee: ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma, Genentech, a member of the Roche Group, Takeda Pharmaceuticals USA Inc. Dr Smith — Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc. Dr Williams — Advisory Committee: AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Kymera Therapeutics, TG Therapeutics Inc; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.